PB@LC/D/siR is synthesized by cross-linking for docetaxel and siSREBP1 delivery fused with PCa cell membranes and bone marrow mesenchymal stem cells, which show the enhanced antitumor effects in bone metastatic castration-resistant PCa, with the characteristics of deep tumor penetration, high safety, and bone protection via downregulation of SREBP-1 and SCD-1 at the mRNA level (156). The gene discussed is SCD; the disease is neoplasm.